Stoke Therapeutics (STOK) Other Non-Current Assets (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Other Non-Current Assets of $3.2 million for Q1 2026, up 347.57% year-over-year from $721000.0 in Q1 2025, and up 1321.59% quarter-over-quarter from $227000.0 in Q4 2025.
Powered by 
Analysis
Stoke Therapeutics (STOK) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Other Non-Current Assets history runs 9 years deep, the most recent figure standing at $3.2 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 347.57% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (up 347.57% YoY), while the FY2025 annual figure was $227000.0, down 68.52% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $3.2 million, up from $227000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $3.2 million in Q1 2026, with the low at $227000.0 in Q4 2025.
- The 5-year median for Other Non-Current Assets is $569000.0 (2022), against an average of $732176.5.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets soared 881.03% in 2022, then plunged 68.52% in 2025.
- Stoke Therapeutics' Other Non-Current Assets stood at $569000.0 in 2022, then changed by 0.0% to $569000.0 in 2023, then gained by 26.71% to $721000.0 in 2024, then tumbled by 68.52% to $227000.0 in 2025, then jumped by 1321.59% to $3.2 million in 2026.
- Business Quant data shows STOK's Other Non-Current Assets at $3.2 million in Q1 2026, $227000.0 in Q4 2025, and $721000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Stoke Therapeutics | 1.96 Bn | 1.66 Bn | - | 3.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.23 Mn |
| Mar 31, 2026 | 3.23 Mn |
| Dec 31, 2025 | 227,000.00 |
| Sep 30, 2025 | 721,000.00 |
| Jun 30, 2025 | 721,000.00 |
| Mar 31, 2025 | 721,000.00 |
| Dec 31, 2024 | 721,000.00 |
| Sep 30, 2024 | 494,000.00 |
| Jun 30, 2024 | 494,000.00 |
| Mar 31, 2024 | 569,000.00 |
| Dec 31, 2023 | 569,000.00 |
| Sep 30, 2023 | 569,000.00 |
| Jun 30, 2023 | 569,000.00 |
| Mar 31, 2023 | 569,000.00 |
| Dec 31, 2022 | 569,000.00 |
| Sep 30, 2022 | 569,000.00 |
| Jun 30, 2022 | 569,000.00 |
| Mar 31, 2022 | 569,000.00 |
| Dec 31, 2021 | 569,000.00 |
| Sep 30, 2021 | 569,000.00 |